Mimetas and Hubrecht Organoid Technology to develop and market Organoids-on-a-Chip

Mimetas and Hubrecht Organoid Technology (HUB) announced that they entered into a strategic collaboration to market organoid models on a Chip. The agreement includes a license to MIMETAS to market HUB Organoids in an assay ready format, as well as a collaborative effort to develop disease-specific models.

"We're delighted and proud that we could transition our long-standing collaboration with the group of Professor Hans Clevers into a commercial proposition," says MIMETAS CEO Paul Vulto. "The adult stem cell biology and Organoid technology of HUB is the very best in the world. By combining it with our OrganoPlate technology in an assay-ready format, the technology becomes available to researchers from any laboratory in the world.”

“We are excited to work with MIMETAS and add a range of new assay systems to the HUB Organoid platform,” says Dr. Rob Vries, CEO at HUB. “The OrganoPlate platform is unrivaled in its field. It is a perfect fit with our biology and enhances ease of use, imageability, and screenability of complex Organoid models. Together we will develop diseased and healthy patient-relevant models that serve the needs of the drug development industry.”

Figures on the right: Human colon organoid in MIMETAS OrganoPlates. Organoids are grown from adult stemcells derived from donor tissue. The organoids are grown as a tube in the MIMETAS OrganoPlate, allowing access to both the basal and apical side of the mini-gut. The MIMETAS platform does not comprise any artificial membranes and allows for excellent imaging. 

Source: Mimetas

‹ News overview